Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-Q (Unaudited Quarterly Report)
Reporting Period: Three and nine months ended December 31, 2010
Business Overview: Repligen is an integrated biopharmaceutical company focused on bioprocessing products (recombinant Protein A) and the development of therapies for neurology and gastroenterology. Revenue is derived from product sales, royalties (primarily from Bristol-Myers Squibb for Orencia), and sponsored research grants.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2010 | Nine Months Ended Dec 31, 2010 |
|---|---|---|
| Total Revenue | $7,067,789 | $21,384,639 |
| Net Income (Loss) | $375,916 | $1,987,178 |
| Operating Income (Loss) | $296,805 | $1,712,431 |
| EPS (Diluted) | $0.01 | $0.06 |
| Cash & Cash Equivalents | $9,794,509 | $9,794,509 (Balance Sheet) |
| Total Marketable Securities | $50,490,547 (Amortized Cost) | $50,490,547 (Amortized Cost) |
| Total Assets | $73,098,789 | $73,098,789 |
| Total Liabilities | $4,217,242 | $4,217,242 |
| Working Capital | $55,563,264 | $55,563,264 |
Cash Flow (Nine Months Ended Dec 31, 2010):
- Net cash provided by operating activities: $1,787,683
- Net cash used in investing activities: $(4,488,122)
- Net cash used in financing activities: $(31,092)
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 26% ($1.45M) for the quarter and 33% ($5.29M) for the nine-month period compared to the prior year.
- Product Revenue: Increased 9% ($261k) quarterly and 46% ($3.73M) for the nine months, driven by increased orders from the largest bioprocessing customer.
- Royalty Revenue: Increased due to higher sales of Bristol-Myers Squibb's Orencia. Quarterly royalty revenue was $2.75M vs. $2.29M; nine-month revenue was $7.74M vs. $6.68M.
- Other Revenue: Included $733k in one-time grants under the Qualifying Therapeutic Discovery Project Program and $461k in sponsored research revenue for the quarter, with no comparable revenue in the prior year quarter.
- Profitability: The company returned to profitability, reporting net income of $376k for the quarter and $1.99M for the nine months, compared to net losses of $349k and $2.43M in the prior year periods. This was driven by revenue growth and reduced R&D spending.
- Operating Expenses: Total operating expenses decreased 3% ($216k) for the quarter and 2% ($430k) for the nine months.
- R&D Expenses: Decreased 24% ($916k) quarterly and 18% ($1.96M) for the nine months due to the completion of Phase 3 clinical operations for RG1068 and reduced activity in the RG2417 trial.
- SG&A Expenses: Increased 15% ($265k) quarterly and 9% ($460k) for the nine months due to increased headcount and business development costs.
- Investment Income: Decreased 51% ($95k) for the quarter and 61% ($449k) for the nine months due to lower interest rates.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management believes current cash and investment balances (approx. $60.3M total) are adequate to meet needs for the foreseeable future. Future capital requirements depend on clinical study success, R&D scope, and potential acquisitions.
- Unusual Items:
- One-time Grants: Recognized $733k in one-time grants under the Patient Protection and Affordability Care Act during the quarter.
- Tax Benefit: Recorded an $835k income tax benefit in the prior year (2009) due to the Worker, Homeownership, and Business Assistance Act of 2009, which is not present in the current period. Current effective tax rate is estimated at 0% due to net operating loss utilization.
- Risks:
- Revenue Concentration: Bristol-Myers Squibb royalties represented 43% of total revenue for the quarter. The largest bioprocessing customer accounted for 41% of total revenue.
- Development Uncertainty: Significant risks exist regarding the success of clinical trials for therapeutic candidates (e.g., RG1068, RG2417, SMA program). No reliable estimate exists for when these candidates will generate revenue.
- Market Volatility: Bioprocessing sales are subject to quarterly fluctuations based on customer production orders and regulatory approvals.
Investor Verification Checklist
- Revenue Concentration: Verify the stability of the top bioprocessing customer and the sales trajectory of Bristol-Myers Squibb's Orencia, which together drive the majority of revenue.
- R&D Pipeline Progress: Monitor the status of the Spinal Muscular Atrophy (SMA) program and other therapeutic candidates to assess future revenue potential beyond royalties and bioprocessing.
- Cash Burn vs. Runway: Confirm that operating cash flow remains positive and that the $60M+ cash position is sufficient to fund R&D without immediate dilution, given the lack of product revenue from drug candidates.
- Grant Sustainability: Assess the likelihood of recurring revenue from government grants (e.g., Qualifying Therapeutic Discovery Project Program) versus one-time recognition.
- Inventory Valuation: Review inventory levels ($1.94M) and provisions for obsolescence, as manufacturing is done to order but demand fluctuations can impact valuation.